二、项目对公司的影响 上述原药及中间体的建成投产符合公司的战略规划，有助于进一步丰富公司 海利尔药业集团股份有限公司 关于子公司青岛恒宁生物二期项目部分产品试生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海利尔药业集团股份有限公司（以下简称"公司"）所属全资子公司青岛恒 宁生物科技有限公司（以下简称"青岛恒宁生物"） 1500 吨/年呋虫胺项目及 配套设施已完成工程主体建设及设备安装、调试工作，近日试生产方案经专家评 审通过并经相关主管部门备案后，符合试生产条件，将正式进入试生产阶段。 一、 基本情况 公司第四届董事会第五次会议审议通过《关于全资子公司重大项目投资的议 案》，公司决定以全资子公司青岛恒宁生物实施主体投资建设青岛恒宁生物二期 项目。 结合战略发展规划以及青岛恒宁实际情况，为更好的保障公司原药及中间体 持续发展，加强自动化生产线的引进和投资，决定变更调整青岛恒宁新建项目产 能和规划设计，详情见公司于 2023 年 4 月 28 日发布的《海利尔药业集团股份有 限公司关于全资子公司重大投资项目变更的公告 ...

证券代码：603639 证券简称：海利尔 公告编号：2024-053 海利尔药业集团股份有限公司 关于证券事务代表辞去职务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海利尔药业集团股份有限公司（以下简称"公司"）董事会于近日收到证券 事务代表卢红领先生的书面辞任报告，卢红领先生因工作调整，申请辞去公司证 券事务代表职务，该辞任申请自送达董事会之日起生效。辞去上述职务后，卢红 领先生将继续在公司其他岗位任职。 特此公告。 海利尔药业集团股份有限公司董事会 2024 年 12 月 25 日 1 公司董事会对卢红领先生在职期间所做出的工作表示衷心的感谢。 ...

本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 107,760 股 | 107,760 | 股 | 2024 | 年 | 12 | 月 | 27 | 日 | 一、本次限制性股票回购注销的决策与信息披露 证券代码：603639 证券简称：海利尔 公告编号：2024-051 海利尔药业集团股份有限公司 关于股权激励限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：根据公司 2021 年限制性股票激励计划相关规定，公司部 分激励对象已不符合激励条件，公司拟对该激励对象已获授但尚未解锁的限制性 股票进行回购注销。 根据公司 2021 年第一次临时股东大会的授权，2024 年 10 月 28 日，公司召 开第五届董事会第六次会议和第五届监事会第六次会议，审议通过《关于回购注 销部分激励对象已获授但尚未解锁的限制 ...

Group 1: Core Competitiveness - The company has integrated capabilities in formulation, active ingredients, and intermediates, excelling in R&D, engineering, production, and sales [3] - The product range is diverse, with a focus on developing major formulations to meet market demands, particularly in pest and weed control [3] - The R&D team is well-structured, covering all aspects of pesticide development, making it one of the most comprehensive pesticide R&D centers in China [3] Group 2: Overseas Business Expansion - The company is actively expanding its overseas business, guided by a "domestic and international integration" strategy [4] - Efforts include enhancing the operational team for international markets and strengthening partnerships with multinational companies [4] Group 3: Product Performance and Sales - In the first three quarters, pesticide sales increased by 2%, while fertilizer sales surged by 60.87% [5] - Average selling prices for pesticides decreased by 15.63%, leading to a 13.95% decline in revenue, while fertilizer revenue grew by 27.35% [5] Group 4: Future Product Development - The company plans to launch 12 new active ingredients within the next three years, with ongoing testing for several compounds [6] - The production capacity for the fungicide Pyraclostrobin is expected to reach 15,000 tons, enhancing market competitiveness [4] Group 5: Financial Performance and Challenges - The company faced a decline in net profit and revenue in recent quarters due to market price drops and seasonal sales fluctuations [6] - The total investment in the Hengning project is substantial, with ongoing efforts to improve operational efficiency and product output [6] Group 6: Shareholder Value and Future Plans - The company has distributed approximately 850 million in dividends over the past three years, with a focus on enhancing core competitiveness to create more value for investors [7] - There are no immediate plans for refinancing, and stakeholders are encouraged to monitor company announcements for updates [7]

证券代码：603639 证券简称：海利尔 公告编号：2024-050 海利尔药业集团股份有限公司 关于参加2024年青岛辖区上市公司投资者网上集体接待日 活动暨召开2024年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024年11月28日（周四） 15:00-17:00 会议召开地点：中国证券报中证网（https://www.cs.com.cn） 会议召开方式：网络方式 投资者可登录中国证券报中证网（https://www.cs.com.cn）参与本次互 动交流。 一、说明会类型 海利尔药业集团股份有限公司（以下简称"公司"）已于 2024 年 10 月 29 日 发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 第三季度经营成果、财务状况，公司将参加由青岛证监局与青岛市上市公司协会 联合举办的"2024 年青岛辖区上市公司投资者网上集体接待日活动"，并召开公 司 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 二、说 ...

证券代码：603639 证券简称：海利尔 公告编号：2024-050 海利尔药业集团股份有限公司 关于参加2024年青岛辖区上市公司投资者网上集体接待日 活动暨召开2024年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024年11月28日（周四） 15:00-17:00 会议召开地点：中国证券报中证网（https://www.cs.com.cn） 会议召开方式：网络方式 投资者可登录中国证券报中证网（https://www.cs.com.cn）参与本次互 动交流。 一、说明会类型 海利尔药业集团股份有限公司（以下简称"公司"）已于 2024 年 10 月 29 日 发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 第三季度经营成果、财务状况，公司将参加由青岛证监局与青岛市上市公司协会 联合举办的"2024 年青岛辖区上市公司投资者网上集体接待日活动"，并召开公 司 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 二、说 ...

一、 股份质押以及解除质押情况 证券代码：603639 证券简称：海利尔 公告编号：2024-049 海利尔药业集团股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 海利尔药业集团股份有限公司（以下简称"公司"）控股股东张爱英女士 持有本公司股份为127,253,000股，占公司总股本的37.43%，本次办理部分股份 质押及解除质押后，张爱英女士累计质押公司股份1,460,000股，占其持有公司 股份总数的1.15%，占公司总股本的0.43%。 截至本公告日，张爱英及其一致行动人葛尧伦、葛家成、青岛合意投资 中心（有限合伙）合计直接持有公司股份219,641,039股，占公司总股本的64.60%。 本次质押及解除质押后，张爱英及其一致行动人葛尧伦、葛家成、青岛合意投资 中心（有限合伙）直接持有的公司股份中处于质押状态的股份累计数为1,460,000 股，占其合计所持公司股份总数的0.66%，占公司总股本的0.43%。 4、股东累计质押股份情况 截至公告披露日 ...

证券代码：603639 证券简称：海利尔 公告编号：2024-046 海利尔药业集团股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的事由 债权申报所需材料包括：公司债权人可持证明债权债务关系存在的合同、协 议及其他凭证的原件及复印件到公司申报债权。债权人为法人的，需同时携带法 1 人营业执照副本原件及复印件、法定代表人身份证明文件；委托他人申报的，除 上述文件外，还需携带法定代表人授权委托书和代理人有效身份证的原件及复印 件。债权人为自然人的，需同时携带有效身份证的原件及复印件；委托他人申报 的，除上述文件外，还需携带授权委托书和代理人有效身份证件的原件及复印件。 债权申报具体方式如下： 海利尔药业集团股份有限公司（以下简称"公司"）于 2024 年 10 月 28 日 召开的第五届董事会第六次会议审议通过了《关于回购注销部分激励对象已获授 但尚未解锁的限制性股票的议案》。公司有 27 名激励对象不再具备激励对象资 格，1 名激励对象不满足限制性股票的解 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥807,666,134.16, a decrease of 22.65% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥33,750,708.74, down 69.71% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥16,186,142.43, a decline of 83.45% compared to the same period last year[2]. - Basic earnings per share for Q3 2024 were ¥0.10, representing a decrease of 70.68% year-on-year[3]. - The weighted average return on equity for Q3 2024 was 0.99%, a decrease of 2.55 percentage points compared to the previous year[3]. - Total operating revenue for the first three quarters of 2024 was CNY 3,213,879,407.17, a decrease of 13.3% compared to CNY 3,707,271,408.11 in the same period of 2023[14]. - Net profit for the third quarter of 2024 was CNY 195,873,110.79, a decline of 55.7% compared to CNY 442,221,155.56 in the same quarter of 2023[16]. - The total comprehensive income attributable to the parent company for the first three quarters of 2024 is CNY 195,831,476.49, a decrease from CNY 442,183,847.63 in the same period of 2023, representing a decline of approximately 55.7%[17]. - Basic and diluted earnings per share for the first three quarters of 2024 are CNY 0.58, down from CNY 1.30 in the same period of 2023, indicating a decrease of about 55.4%[17]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥6,507,526,292.40, an increase of 0.91% from the end of the previous year[3]. - The total assets of the company as of the end of the third quarter of 2024 were CNY 6,507,526,292.40, slightly up from CNY 6,448,631,718.85 at the end of the previous year[13]. - Total liabilities decreased to CNY 3,066,214,870.60 from CNY 3,066,491,911.12 year-over-year[13]. - The company's total equity as of the end of the third quarter of 2024 was CNY 3,441,311,421.80, up from CNY 3,382,139,807.73 in the previous year[13]. - The company reported a significant increase in expected liabilities, rising to CNY 244,987,226.45 from CNY 40,970,555.31, indicating potential future financial obligations[12]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥60,074,495.09, down 89.63% year-on-year[6]. - Cash inflows from operating activities for the first three quarters of 2024 total CNY 2,337,499,929.23, compared to CNY 2,823,234,520.03 in the same period of 2023, reflecting a decline of approximately 17.2%[19]. - Net cash generated from operating activities for the first three quarters of 2024 is CNY 60,074,495.09, significantly lower than CNY 579,122,250.94 in the same period of 2023, a decrease of about 89.6%[19]. - Net cash outflow from investing activities for the first three quarters of 2024 is CNY -472,546,429.52, compared to CNY -544,011,574.81 in the same period of 2023, indicating a slight improvement[20]. - Net cash generated from financing activities for the first three quarters of 2024 is CNY 526,477,899.42, a turnaround from a net outflow of CNY -94,288,754.00 in the same period of 2023[20]. - The cash and cash equivalents at the end of the first three quarters of 2024 amount to CNY 286,238,262.92, compared to CNY 280,678,286.82 at the end of the same period in 2023, showing a slight increase[20]. - The company received CNY 733,052,000.00 from the recovery of investments in the first three quarters of 2024, a decrease from CNY 2,215,205,197.53 in the same period of 2023, representing a decline of approximately 66.9%[19]. - Cash received from other operating activities in the first three quarters of 2024 is CNY 57,561,360.35, compared to CNY 28,870,145.54 in the same period of 2023, indicating an increase of about 99.2%[19]. - The company reported cash outflows for purchasing goods and services amounting to CNY 1,779,680,576.37 in the first three quarters of 2024, slightly higher than CNY 1,776,712,874.77 in the same period of 2023[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,783[8]. - The largest shareholder, Zhang Aiying, holds 127,253,000 shares, accounting for 37.43% of the total shares[8]. - The company has no significant changes in the top 10 shareholders' participation in margin trading and securities lending[9]. - The company maintains a stable shareholder structure with no changes in major shareholders' participation in securities lending activities[9]. Non-Recurring Gains and Expenses - Non-recurring gains for Q3 2024 included government subsidies amounting to ¥1,999,927.00[4]. - The company reported a total of ¥17,564,566.31 in non-recurring gains for the year-to-date[5]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 162,611,784.52, compared to CNY 192,801,822.21 in the same period of 2023, reflecting a decrease of 15.6%[16]. Market Conditions - The company experienced a significant decline in net profit due to market downturns and price reductions in certain pesticide products[6]. - The company has not reported any significant new strategies or product developments in the current quarter[10].

2024 年三季度主要经营数据公告 海利尔药业集团股份有限公司 证券代码：603639 证券简称：海利尔 公告编号：2024-044 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司行业信息披露指引第十三号——化工》《上 海证券交易所上市公司自律监管指引第 3 号——行业信息披露》的要求，海利尔 药业集团股份有限公司（以下简称"公司"）现将 2024 年三季度主要经营数据披 露如下： 一、主要产品的产量、销量及收入实现情况（不含税） 二、主要产品的价格变动情况（不含税） | 主要产品 | 2024 年 | 1 | 至 | 9 | 月 | 2023 年 9 | 1 | 至 | 月 | 变动比率（%） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 平均售价（元/吨） | | | | 平均售价（元/吨） | | | | | | 农药 | 67,181.87 | | | | | 79,631.90 | ...